Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Addiction (Abingdon, England)|December 18, 2020
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexoneKristin Klemmetsby Solli, Arild Opheim, Zill-E-Huma Latif, et al.
BMC Pharmacology & Toxicology|April 29, 2016
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)Nikolaj Kunøe, Arild Opheim, Kristin Klemmetsby Solli, et al.
European Addiction Research|September 27, 2021
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and RelapseZhanna Gaulen, Ida Halvorsen Brenna, Lars Thore Fadnes, et al.
Contemporary Clinical Trials|October 21, 2023
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trialArild Opheim, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.
JAMA Psychiatry|October 20, 2017
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority TrialLars Tanum, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.
The American Journal on Addictions|February 1, 2019
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up studyZill-E-Huma Latif, Kristin K Solli, Arild Opheim, et al.
Addiction (Abingdon, England)|May 29, 2018
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trialKristin Klemmetsby Solli, Zill-E-Huma Latif, Arild Opheim, et al.
JAMA Psychiatry|December 20, 2018
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up StudyZill-E-Huma Latif, Jurate Šaltyte Benth, Kristin Klemmetsby Solli, et al.
The American Journal on Addictions|September 6, 2021
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical TrialArild Opheim, Zhanna Gaulen, Kristin Klemmetsby Solli, et al.
European Addiction Research|July 20, 2016
Interest in Extended Release Naltrexone among Opioid UsersKamni Sharma Haase, Nikolaj Kunøe, Arild Opheim, et al.
Pageof 2